Compare RCMT & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RCMT | KALA |
|---|---|---|
| Founded | 1971 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 196.0M | 172.0M |
| IPO Year | 1997 | 2017 |
| Metric | RCMT | KALA |
|---|---|---|
| Price | $22.00 | $2.25 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $36.00 | $31.50 |
| AVG Volume (30 Days) | 72.9K | ★ 1.2M |
| Earning Date | 04-03-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 27.38 | ★ 67.39 |
| EPS | ★ 0.52 | N/A |
| Revenue | ★ $186,737,000.00 | N/A |
| Revenue This Year | $11.89 | N/A |
| Revenue Next Year | $12.46 | N/A |
| P/E Ratio | $41.15 | ★ N/A |
| Revenue Growth | ★ 5.83 | N/A |
| 52 Week Low | $17.26 | $0.07 |
| 52 Week High | $32.50 | $20.58 |
| Indicator | RCMT | KALA |
|---|---|---|
| Relative Strength Index (RSI) | 32.23 | 59.31 |
| Support Level | $21.11 | $0.32 |
| Resistance Level | $25.31 | $3.96 |
| Average True Range (ATR) | 1.43 | 0.37 |
| MACD | -0.65 | -0.07 |
| Stochastic Oscillator | 12.14 | 7.27 |
RCM Technologies Inc is a provider of business and technology solutions designed to enhance and maximize the operational performance of its customers. It operates in three segments: Specialty Health Care, Engineering, and Life Sciences, Data and Solutions (LS&D). The company generates maximum revenue from the Specialty Health Care segment that provides staffing solutions including medical healthcare professionals, health information management professionals, nurses, paraprofessionals, physicians, and therapists. Geographically, it derives a majority of its revenue from the United States and also has a presence in Canada, Puerto Rico, the Philippines, and Europe.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.